Vaxart Newsroom

Buy Rating Affirmed for Vaxart Amidst Promising Norovirus Vaccine Developments and Market Opportunity

TipRanksJul 9 07:29 ET

B. Riley Raises Price Target on Vaxart to $2.50 From $2, Maintains Buy Rating

MT NewswiresJun 14 07:42 ET

Vaxart Spikes as B. Riley Upgrades at Long Last After BARDA Funding

Seeking AlphaJan 31 14:13 ET

Vaxart Analyst Ratings

BenzingaJan 31 09:46 ET

Analysts' Top Healthcare Picks: Vaxart (VXRT), Palisade Bio (PALI)

TipRanksJan 31 07:40 ET

Analyst Holds Vaxart Stock Rating Amid Positive Clinical Trials and Robust Vaccine Development Prospects

TipRanksNov 7, 2023 10:15 ET

Vaxart (VXRT) Receives a Buy From Cantor Fitzgerald

TipRanksSep 10, 2023 14:25 ET

B.Riley Financial Remains a Hold on Vaxart (VXRT)

TipRanksSep 7, 2023 14:45 ET

Cantor Fitzgerald Reiterates Overweight on Vaxart, Maintains $4 Price Target

BenzingaSep 7, 2023 09:21 ET

Vaxart Analyst Ratings

BenzingaSep 7, 2023 09:21 ET

Cantor Fitzgerald Maintains Overweight on Vaxart, Lowers Price Target to $4

BenzingaAug 7, 2023 09:07 ET

Vaxart Analyst Ratings

BenzingaAug 7, 2023 09:02 ET

B.Riley Financial Remains a Hold on Vaxart (VXRT)

TipRanksJul 7, 2023 11:45 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vaxart (VXRT) and Tarsus Pharmaceuticals (TARS)

TipRanksMay 8, 2023 12:25 ET

Jefferies Keeps Their Buy Rating on Vaxart (VXRT)

TipRanksMar 29, 2023 08:21 ET

B.Riley Financial Sticks to Its Hold Rating for Vaxart (VXRT)

TipRanksMar 16, 2023 12:51 ET

B.Riley Financial Keeps Their Hold Rating on Vaxart (VXRT)

TipRanksFeb 27, 2023 17:41 ET

Vaxart Analyst Ratings

Benzinga Analyst RatingsDec 19, 2022 08:32 ET

B. Riley Securities Maintains Neutral on Vaxart, Lowers Price Target to $1.5

Benzinga Real-time NewsDec 19, 2022 08:31 ET

Vaxart Is Maintained at Overweight by Cantor Fitzgerald

Dow JonesSep 2, 2022 08:44 ET